| Management target | Revenue FY28 |
|---|
| Revenue growth | 31% YoY in H1; ₹2,206 Cr in Q2. |
|---|---|
| Margins | EBITDA margin expanded to 34.5% in Q2. |
| Demand visibility | Strong pipeline in CDMO; robust demand for peptide synthesis. |
| Management confidence | Balanced and strategic focus on complex new modalities. |
Growth
CDMO revenue surged 86% YoY, while Affordable Medicine segments grew 15% with stabilizing pricing.
Outlook
Management maintains guidance for 60%+ gross margins and 30%+ EBITDA margins for FY27.
Risks
Substantial growth capex of ₹864 Cr in H1 keeps net debt high and free cash flow negative.
Earnings Call Transcript filed with NSE, NSE: LAURUSLABS. Summary written with AI assistance from the document.
Laurus Labs Ltd: key numbers
- Share price
- ₹2,244.00
- Market cap
- ₹1,21,246 Cr
- Revenue (annual)
- ₹6,813 Cr
- Net profit (annual)
- ₹888.8 Cr
- P/E (TTM)
- 90.5×Sector 48.7×
- Promoter holding
- 27.47%+0.00% QoQ
- FII holding
- 30.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Laurus Labs Ltd
All →Laurus Labs Results Update
Laurus Labs reported H1 FY27 revenue of ₹4,233 Cr and EBITDA of ₹1,406 Cr. The company acquired Galenvs Sciences and SI&C Resins to expand CDMO capabilities.
- SPPS peptide synthesis capacity
- 16000 L
Laurus Labs Investor Presentation: Key Takeaways
Q2/H1 FY27: H1 revenue ₹4,233 Cr (+31%), EBITDA ₹1,406 Cr (33.2% margin), PAT ₹809 Cr (+126%). CDMO-led growth; ₹3,000 Cr+ capex planned FY27-28.
Laurus Labs Dividend
Laurus Labs approved a Re. 1.00 per share interim dividend for FY 2026-27. Record date is November 6, 2026; payment on or after November 19, 2026.
Laurus Labs Management Change
Laurus Labs appointed Mr. Kundan Kumar Jha as Joint Company Secretary effective November 1, 2026, following Board approval. The KMP appointment advances the company's succession planning process.
Laurus Labs Acquisition Worth ₹32.5 Cr
Laurus Labs approved acquiring 52% of SI & C Resins for Rs. 32.50 Crore. The acquisition makes SI&C a subsidiary for peptide resin manufacturing.
- Value
- ₹32.50 Cr
Laurus Labs Acquisition Worth ₹35.63 Cr
Laurus Labs approved buying 60% of Canada-based CRO Galenvs Sciences for USD 3.75 million (₹35.63 Cr). The deal adds an oligonucleotide R&D arm and North American presence.
- Value
- ₹35.63 Cr